Author: Abhay Panchal

Novo Nordisk has signed a $1 billion deal with Lexicon Pharmaceuticals for exclusive global rights to LX9851, an experimental oral drug targeting obesity and metabolic disorders. The agreement gives Lexicon $75 million upfront, with additional milestone-based payments. LX9851 targets fat metabolism and has shown enhanced weight loss effects when combined with Novo’s semaglutide (Wegovy). The deal is part of Novo Nordisk’s aggressive strategy to expand its obesity portfolio amid rising global demand and competition from Eli Lilly’s Zepbound.

Read More

The U.S. healthcare system is facing a looming crisis as a large portion of its physician workforce nears retirement, with over 30% of doctors aged 60 or older and a projected shortage of more than 81,000 physicians by 2035. Despite rising medical school enrollment, outdated Medicare residency caps and increasing burnout are limiting new physician supply, while many young medical professionals are opting out of patient care entirely. Experts warn that without urgent changes—such as expanding training programs, embracing advanced practice providers, leveraging technology, and improving workplace conditions—the system may struggle to meet the growing healthcare demands of an aging…

Read More

With 30% of the population already affected and projections soaring to 41.4% by 2050, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is rapidly emerging as the silent giant of modern chronic disease. More than a liver issue, MASLD is now seen as a complex metabolic disease requiring collaboration across hepatology, endocrinology, primary care, nutrition, and more. Harvard’s Dr. Christos Mantzoros says: “We don’t have enough experts to treat these patients… We need collaboration, training, and professional societies building bridges.”

Read More

In this episode, Venture Science founding partner Matt Oguz sits down with the founder & CEO of Jona, a trailblazing company unlocking the secrets of the microbiome to drive personalized health insights. Explore how gut health is rapidly becoming central to preventative medicine, and how microbiome diagnostics are shedding new light on chronic conditions like: You’ll also learn how Jona is turning complex microbiome data into actionable guidance—and why this matters for the future of health and wellness.

Read More

This article explores how electronic health records (EHRs), while beneficial for data access and care coordination, contribute significantly to provider burnout in inflammatory bowel disease (IBD) care. Tasks like documentation, chart review, and in-basket messaging consume excessive time, especially for IBD specialists. Despite prior efforts—including standardized templates, order sets, and collaborative networks like IBD Qorus and ImproveCareNow—barriers persist due to varying platforms and lack of standardization.

Read More